2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...

The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...

See the new treatment that will break a Pfizer monopoly on a drug for heart disease.

The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...

The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...

The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...

BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...